menu
    • menu
    [{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Telazorlimab","moa":"OX40","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ichnos Sciences \/ Glenmark pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sciences \/ Glenmark pharmaceuticals"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ichnos Sciences \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Ichnos Sciences \/ Almirall"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ISB 2001","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ISB 1442","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ISB 1442","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ISB 2001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"STAR-0310","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ichnos Sciences","amount2":0.32000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Astria Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Sciences \/ Astria Therapeutics"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"GRC 54276","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Ichnos Sciences

    Menu

    Ichnos Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRC 54276,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ichnos and Glenmark Collaborate for Innovation in Cancer Treatment

                            Details : The collaboration between Ichnos and Glenmark aims to enhance cancer drug discovery, focusing on novel biologics and small molecules like GRC 54276 for hematological malignancies.

                            Brand Name : GRC 54276

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : GRC 54276,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STAR-0310

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Astria Therapeutics

                            Deal Size : $320.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

                            Details : Under the terms of the license agreement, Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.

                            Brand Name : STAR-0310

                            Molecule Type : Large molecule

                            Upfront Cash : $15.0 million

                            October 11, 2023

                            Lead Product(s) : STAR-0310

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Astria Therapeutics

                            Deal Size : $320.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ichnos Sciences Receives Orphan Drug Designation for First-in-class Trispecific Antibody, ISB 2001

                            Details : ISB 2001, Ichnos' third clinical-stage asset to receive ODD for the treatment of multiple myeloma, is the company's first BCMA x CD38 x CD3 TREAT™ trispecific antibody based on the company's proprietary BEAT® platform, which enables the development of...

                            Brand Name : ISB 2001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 07, 2023

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 1442

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) antibody Innate C...

                            Details : ISB 1442 is a biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47, for the treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).

                            Brand Name : ISB 1442

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 21, 2023

                            Lead Product(s) : ISB 1442

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 1442

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442

                            Details : ISB 1442 is a biparatopic bispecific antibody that combines two proprietary anti-CD38 binding arms, each targeting different regions on CD38, with an antagonistic anti-CD47 arm, making it equivalent to a trispecific antibody.

                            Brand Name : ISB 1442

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 28, 2022

                            Lead Product(s) : ISB 1442

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ichnos Sciences Announces Selection Of Trispecific Antibody Isb 2001 As Next Clinical Candidate For Relapsed/R...

                            Details : In vitro studies showed that ISB 2001 exhibited increased killing potency of tumor cells compared to all tested antibodies that are either currently approved therapeutics for multiple myeloma or being tested in ongoing clinical studies.

                            Brand Name : ISB 2001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 09, 2022

                            Lead Product(s) : ISB 2001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISB 880

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Almirall

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class Il-1 RAP Antagonist Monoclona...

                            Details : Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.

                            Brand Name : ISB 880

                            Molecule Type : Large molecule

                            Upfront Cash : $23.6 million

                            December 14, 2021

                            Lead Product(s) : ISB 880

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Almirall

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Ichnos Sciences

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telazorlimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis At The...

                            Details : The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.

                            Brand Name : ISB 830

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2021

                            Lead Product(s) : Telazorlimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth